101349-30-8

Basic information

• Product Name: methyl 4-amino-3-chlorobenzene-1-acetate
• Synonyms: methyl 4-amino-3-chlorobenzene-1-acetate
• CAS NO: 101349-30-8
• Molecular Weight: 199.637
• Mol File: 101349-30-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 4-amino-3-chlorobenzene-1-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-amino-3-chlorobenzene-1-acetate(101349-30-8)
• EPA Substance Registry System: methyl 4-amino-3-chlorobenzene-1-acetate(101349-30-8)

Safety Data

• Hazardous Substances Data: 101349-30-8(Hazardous Substances Data)

Upstream product

• 18699-02-0 4-acetamidophenylacetic acid 
• 67-56-1 methanol 
• 59235-32-4 (3-chloro-4-acetamino-phenyl)-acetic acid 
• 1197-55-3 4-aminophenylacetic acid 
• 1878-65-5 3-chlorophenylacetic acid 
• 7439-89-6 iron 
• 97522-06-0 methyl (3-chloro-4-nitrophenyl)acetate 
• 53088-68-9 methyl 3-chlorophenylacetate 

Downstream Products

• 317364-40-2 methyl 3-chloro-4-[N'-(2-chlorophenyl) ureido]phenylacetate 
• 317356-69-7 methyl 4-[N'-(2bromophenyl)ureido]-3-chlorophenylacetate 
• 317364-37-7 methyl 3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetate 
• 441714-88-1 C₂₈H₃₀ClF₂N₃O₄S 
• 441714-85-8 C₂₈H₃₁ClFN₃O₄S 
• 441712-30-7 trans-4-[1-[[3-chloro-4-(6-fluoro-2-benzothiazolyl)aminophenyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid 
• 441712-29-4 trans-4-[1-[[4-(2-benzothiazolyl)amino-3-chlorophenyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid 

Relevant articles and documents

2-PHENYL BENZOYLAMIDES

Compounds of Formula I that inhibit microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and their uses in the treatment of diseases linked thereto in animals are described herein.

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.